G8 Education Ltd

Rebound after heavy fall: G8 Education Ltd.’s (ASX: GEM) stock that lost over 23% on December 04, 2017, regained attention but on a positive side rallying over 5.3% on December 05, 2017. Many market experts and broker still are positive on the stock despite the FY17 earnings downgrade (to around $160 million from mid- $170 million) highlighted by the group owing to issues relating to occupancy levels and other investments. However, there is still a growth of 5% forecasted for the year. We believe that there is long-term value in the stock while some short-term pressure may prevail, and give a “Hold” at the current price of $3.58
 

CSL Ltd

R&D Updates: Health Care group CSL’s (ASX: CSL) stock edged lower on December 05, 2017 while the group came out with its R&D operational briefings. CSL has planned an expenditure of $US550 million ($A720 million) on phase three clinical trials of a new treatment for preventing secondary heart attacks that are quite lethal than the initial attacks. The group also indicated that Bio21 expansion is slated for completion in Feb 2018. The group has many phases planned for its products in the next two years. For instance, Phase I study (healthy volunteers) for CSL730, recombinant Fc multimer, is planned to commence in Q1 2018. Year 2018 is also a crucial year with regards to its HIZENTRA® CIDP product launch (pending approval). Progress on its breakthrough therapy, CSL112, is also said to be the largest ever undertaken by CSL. Rising 52% in last one year (as at December 04, 2017) and peaking close to 52-week high level, we believe that the stock is “Expensive” at the current price of $144.37 and would review it again for any dip.
 

Breakthrough Medicines (Source: Company Reports)

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.